182919-58-0

Basic information

• Product Name: 1-BENZYLPIPERIDINE-3-CARBOHYDRAZIDE
• Synonyms: 1-BENZYLPIPERIDINE-3-CARBOHYDRAZIDE;1-(Phenylmethyl)-3-piperidinecarboxylic hydrazide
• CAS NO: 182919-58-0
• Molecular Formula: C₁₃H₁₉N₃O
• Molecular Weight: 233.31
• Mol File: 182919-58-0.mol

Chemical Properties

• Boiling Point: 415.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.149±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.23±0.20(Predicted)
• CAS DataBase Reference: 1-BENZYLPIPERIDINE-3-CARBOHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYLPIPERIDINE-3-CARBOHYDRAZIDE(182919-58-0)
• EPA Substance Registry System: 1-BENZYLPIPERIDINE-3-CARBOHYDRAZIDE(182919-58-0)

Safety Data

• Hazardous Substances Data: 182919-58-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzylpiperidine-3-carbohydrazide is used as a building block for the synthesis of various pharmaceutical compounds due to its versatile chemical structure and potential therapeutic properties.
Used in Antituberculosis Applications:
BPCH is used as an anti-tuberculosis agent, showing potential in the development of new treatments for tuberculosis by targeting the growth and survival of Mycobacterium tuberculosis, the causative agent of the disease.
Used in Anticancer Applications:
1-Benzylpiperidine-3-carbohydrazide is used as an anticancer agent, exhibiting inhibitory effects on the growth of various cancer cell lines. Its potential role in cancer treatment is currently under investigation.
Used in Neurodegenerative Disease Treatment:
BPCH is used in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's, where it has shown promise in mitigating the progression of these conditions through its potential neuroprotective and restorative effects.
Used in Industrial Applications:
1-Benzylpiperidine-3-carbohydrazide is used as a corrosion inhibitor in various industrial applications, where it helps to prevent the degradation of materials and extend the lifespan of equipment and structures.

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 72551-53-2 ethyl 1-benzylpiperidine-3-carboxylate 

Downstream Products

• 919100-20-2 (3RS)-1-(phenylmethyl)-3-piperidinecarboxylic acid 2-[(methylamino)thioxomethyl]hydrazide 
• 60407-35-4 1-phenylmethyl-3-aminopiperidine 

Relevant articles and documents

Synthesis, bioactivity and molecular modeling studies on potential anti-Alzheimer piperidinehydrazide-hydrazones

A group of N-benzylpiperidine-3/4-carbohydrazide-hydrazones were designed, synthesized and evaluated for acetylcholinesterase (AChE), butyrylcholinesterase (BuChE)activities, Aβ42 self-aggregation inhibitory potentials, and antioxidant capacities, in vitro. All of the compounds displayed eeAChE and huAChE inhibitory activity in a range of IC50 = 5.68–11.35 μM and IC50 = 8.80–74.40 μM, respectively and most of the compounds exhibited good to moderate inhibitory activity on BuChE enzyme. Kinetic analysis and molecular modeling studies were also performed for the most potent compounds (1g and 1j). Not only the molecular modeling studies but also the kinetic analysis suggested that these compounds might be able to interact with the catalytic active site (CAS)and the peripheral anionic site (PAS)of the enzymes. In the light of the results, compound 1g and compound 1j may be suggested as lead compounds for multifunctional therapy of AD.

Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity

A series of novel quinoline-2-carboxamides 15–28 was synthesized and evaluated in?vitro as dual COXs/LOX inhibitors. Compounds 19 and 27 exhibited the highest potency and selectivity for COX-2 inhibitory activity (IC50?=?1.21 and 1.13?μM, respe

Novel 1,5-diaryl pyrazole-3-carboxamides as selective COX-2/sEH inhibitors with analgesic, anti-inflammatory, and lower cardiotoxicity effects

COX-2 selective drugs have been withdrawn from the market due to cardiovascular side effects, just a few years after their discovery. As a result, a new series of 1,5-diaryl pyrazole carboxamides 19–31 was synthesized as selective COX-2/sEH inhibitors wit

SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS

The present invention relates to the compounds of formula (I): wherein A,B, n, X, Y, Z, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

A convenient route to 1-benzyl 3-aminopyrrolidine and 3-aminopiperidine

1-Benzyl 3-aminopyrrolidine 1 and 1-benzyl 3-aminopiperidine 2 were prepared rapidly mainly in aqueous conditions in 55 and 75% yields, respectively, on a multi-gram scale starting from inexpensive and commercially available starting materials. The key step involved the Curtius rearrangement mediated by sodium nitrite and trifluoroacetic acid of the appropriate acylhydrazides. All the reactions (except LAH reductions) were performed in water.